EMD Serono Acquires PostEra's Oral Fertility Drug Programs
Image
Boston – September 15, 2026 -- EMD Serono, Inc., the U.S. and Canada healthcare business of Merck KGaA, Darmstadt, Germany, has acquired two preclinical fertility drug programs from PostEra, a biotechnology company that uses artificial intelligence for small-molecule drug discovery.
EMD Serono takes over two AI-derived fertility programs from PostEra
The deal covers a class of follicle-stimulating hormone receptor (FSHR) agonists for ovarian stimulation in IVF and a separate class of luteinizing hormone/chorionic gonadotropin receptor (LHCGR) agonists targeting male infertility and ovulation triggering in IVF. Both programs were developed over the past two years using PostEra's Proton AI platform and remain in preclinical development, with safety and efficacy in humans not yet established.